Clinical trials: Chronic Hepatitis B Infections
Inflammatory Bowel Disease, Crohn Disease
Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease
This study aims to determine the prevalence of HBV infection in patients with IBD and rheumatologic disease, and to assess the impact of immunosuppressive therapy on viral load and clinical course of IBD patients.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Rheumatic Diseases
- Trial name
- NCT02128503
- Testing
- HBV DNA level monitoring
- Where
- Hong Kong
- Volunteers
- 430 people
- Sponsor
- Chinese University of Hong Kong
Chronic Hepatitis B
Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients
1. Adefovir add-on therapy is superior to switching to adefovir monotherapy or entecavir 1mg monotherapy for chronic hepatitis B (CHB) patients with lamivudine resistance (LAM-R) 2.
- Trial name
- NCT01491295
- Testing
- Tenofovir disoproxil fumarate, Lamivudine plus adefovir
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Chronic Hepatitis b
Study on Effect of Intestinal Microbiota Transplantation in Chronic Hepatitis B
Chronic hepatitis B(CHB) is a common infectious disease affecting up to 2 billion people worldwide. Around 650 thousand people died of liver failure, cirrhosis and primary liver cancer caused by chronic hepatitis B every year.
- Trial name
- CHB (NCT03429439)
- Testing
- intestinal microbiota transplant, Antiviral Agents
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhongshan Hospital Xiamen University
Chronic Hepatitis b
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy
This is an open label, randomized, multi-center, comparative study. Subjects will be screened prior to study entry to establish eligibility.
- Trial name
- NCT04157257
- Testing
- TDF tablet, Entecavir Tablet, QL-007
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Chronic Hepatitis B
Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B
This is a multi-center phase 3, open-label, parallel-group study designed to evaluate the efficacy, safety and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and varying degrees of…
- Trial name
- NCT00071201
- Testing
- Adefovir Dipivoxil for oral suspension, 2 mg/mL
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B
The outcome of treatment of chronic hepatitis B is determined by viral and host interaction, thus the combination therapy of immunomodulator (PEG-IFN) and potent antiviral drug (entecavir) should improve the response rate.
- Trial name
- NCT01243281
- Testing
- PEG-IFN and entecavir
- Where
- Thailand
- Volunteers
- 126 people
- Sponsor
- Chulalongkorn University
Chronic Hepatitis B
Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States
The objective of this study is to provide open label emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for an additional 5 years (240 weeks) to adults completing study GS-US-203-0107.
- Trial name
- NCT00936715
- Testing
- FTC/TDF
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis b, ALT
Evaluation of Antiviral Indications on Chronic HBV Infection With Different Transaminase Levels
It remains unknown whether antiviral therapy is beneficial for chronic hepatitis B (CHB) with normal or mild ALT.The investigators aim to evaluate the antiviral indications combining liver biopsy and clinical parameters,and…
- Trial name
- NCT03740789
- Where
- China
- Volunteers
- 700 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Chronic Hepatitis b
A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects
This is a phase 1 study in which healthy adult subjects will receive TQA3038 or placebo and will be assessed for safety, tolerability, pharmacokinetics.
- Trial name
- NCT06085053
- Testing
- TQA3038 injection
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Hepatitis B
CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study
This study has the aim of describing viral mutation profiles in patients diagnosed with chronic hepatitis B receiving antihepadnaviral therapy.
- Trial name
- CHARM (NCT00645736)
- Testing
- No intervention
- Where
- Australia
- Volunteers
- 788 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam
This prospective, multicenter, observational study will evaluate the sustained response in patients with HBeAg positive chronic hepatitis B who are treated with Pegasys according to standard of care and in line with the current…
- Trial name
- NCT01886300
- Where
- 3 sites in Vietnam
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C, Decompensated Cirrhosis
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
The primary objectives of this study are to assess the safety and the SVR12 rate of ombitasvir/paritaprevir/ritonavir and dasabuvir with RBV in GT1-infected participants with decompensated cirrhosis.
- Conditions
- Chronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus
- Trial name
- TURQUOISE-CPB (NCT02219477)
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 36 people
- Sponsor
- AbbVie
Hepatitis B, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B
This multicenter, prospective, observational study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) in routine clinical practice in patients with HBeAg-positive or HBeAg-negative chronic hepatitis B.
- Trial name
- NCT01734018
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis b
Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b
This study is to investigate the clinical efficacy and safety of three types of nucleotide/nucleoside analogues in treatment of chronic hepatitis b
- Trial name
- NCT04195074
- Testing
- Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Chronic Hepatitis B
A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus…
- Trial name
- NCT04398134
- Testing
- ABI-H2158, Entecavir (ETV)
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 88 people
- Sponsor
- Assembly Biosciences
Hepatitis B
Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B
This study is being conducted to compare the effectiveness of the combination of valtorcitabine and telbivudine to telbivudine alone in patients with chronic hepatitis B.
- Trial name
- NCT00128544
- Testing
- telbivudine, valtorcitabine
- Where
- 3 sites in Hong Kong, New Zealand and 1 more
- Volunteers
- 130 people
- Sponsor
- Novartis
Hepatitis; Virus, Chronic, Type B
A Clinical Trials to Evaluate the Efficacy and Safety of Tenofovir With and Without DWPUR001 in Patients With HBV
The patient who meets the inclusion/exclusion criteria is assigned to Test1 group or Test 2 group or control group randomly. All subjects take one pill of Viread® Tab.
- Trial name
- NCT02966964
- Testing
- DWPUR001
- Where
- 6 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Uijeongbu St. Mary Hospital
Hepatitis C, Chronic
Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy
The aim of this study is to explore the efficacy and safety of boceprevir -based triple therapy to rescue HCV genotype 1 (HCV GT1)/HBV dually infected patients refractory to previous peginterferon (PEG-IFN) plus ribavirin (RBV)…
- Trial name
- BOLERO-CB (NCT02060058)
- Testing
- Stop trial intervention for boceprevir, PEG-IFN and RBV
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Chronic Hepatitis C
HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity
Objective: The goal is to improve peginterferon sensitivity in previous poor responders. "Sensitivity" here means the host's ability to kill more HCV.
- Trial name
- NCT01377909
- Testing
- statin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bader, Ted, M.D.
Chronic Hepatitis B
Sustained HBsAg and Viral Response in Patients Achieved HBsAg Loss by Interferon Treatment
Chronic hepatitis B (CHB) is a serious liver disease worldwide, and the leading cause of cirrhosis and hepatocellular carcinoma (HCC).HBsAg loss/seroconversion is considered to be the ideal endpoint of antiviral therapy in both…
- Trial name
- NCT02336399
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Beijing Ditan Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.